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Summary 
There is increasing evidence that the complement system plays an important role in 
diabetes and the development of diabetic vascular complications. In particular, 
mannan-binding lectin (MBL) levels are elevated in diabetes patients, and diabetes 
patients with diabetic nephropathy have higher MBL levels than diabetes patients with 
normal renal function. The MBL-associated serine proteases (MASPs) MASP-1, 
MASP-2, and MASP-3, and MBL-associated protein MAp44 have not yet been studied 
in diabetes patients. We therefore measured plasma levels of MASP-1, MASP-2, 
MASP-3, and MAp44 in 30 children with type 1 diabetes mellitus (T1DM) and 17 
matched control subjects, and in 45 adults with T1DM and 31 matched control 
subjects. MASP-1 and MASP-2 levels were significantly higher in children and adults 
with T1DM than in their respective control groups, whereas MASP-3 and MAp44 levels 
did not differ between patients and controls. MASP-1 and MASP-2 levels correlated 
with HbA1c, and MASP levels decreased when glycaemic control improved. Since 
MASP-1 and MASP-2 have been shown to directly interact with blood coagulation, 
elevated levels of these proteins may play a role in the enhanced thrombotic 
environment and consequent vascular complications in diabetes. A
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Introduction 
There is increasing evidence that the complement system, which is a part of the innate 
immune system, plays an important role in diabetes and the development of diabetic 
vascular complications (please refer to the excellent reviews by Phieler et al [1] and 
Hertle et al [2]). Plasma concentrations of several proteins of the complement system 
are elevated in patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes 
mellitus (T2DM), including the central component C3 [3,4]. Furthermore, deposits of 
complement activation products have been found in tissues from diabetes patients 
[5,6]. Many studies have shown that high levels of circulating complement factors and 
increased complement activation are associated with vascular complications of 
diabetes such as cardiovascular disease and diabetic nephropathy. 
We have an interest in the lectin pathway of the complement system, which may play a 
role in the development of these complications. Mannan-binding lectin (MBL) and 
ficolins are the pattern recognition molecules in the lectin pathway. Upon binding of 
MBL or ficolins to a target molecule, activation of the lectin pathway is mediated by the 
MBL-associated serine proteases (MASPs) MASP-1 and MASP-2. The role of MASP-3 
is not yet fully understood.[7-9] Two MBL-associated proteins, MAp19 and MAp44, 
which are alternative splicing variants of the MASP2 and MASP1 genes, respectively, 
have no protease activity. MAp44 was reported to have a regulatory function by 
displacing MASPs from the MBL complex and inhibiting lectin pathway activation. [10, 
11] 
Of the proteins mentioned above, MBL and ficolins  have so far been studied in 
diabetes. MBL levels are elevated in patients with T1DM [12] and T2DM [13]. Among A
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diabetes patients, MBL and H-ficolin levels were higher in patients with diabetic 
nephropathy than in patients with normal renal function [,14-16]. In a prospective study 
high MBL levels were associated with progression to end-stage renal disease [17]. 
This evidence for a role of MBL in diabetes and diabetic vascular complications 
inevitably leads to the question whether levels of MASPs are also altered in diabetes 
and may contribute to diabetes complications. In the lectin pathway, MBL acts through 
its associated serine proteases, and MASPs circulate in plasma to a major extent in 
complex with MBL. Yet MASP levels have never been measured in diabetes patients. 
To our knowledge there is only one study available in which MASP-2 levels were 
measured in patients with T2DM who suffered from myocardial infarction [18]. Patients 
were then followed for a median period of 2.1 years for further cardiovascular events. 
Patients who suffered from cardiovascular events during that period had significantly 
lower MASP-2 levels at admission, but the significant association was lost after 
adjustment for cardiovascular risk factors. We have shown earlier that levels of MASP-
1 and MASP-2 are altered in patients with cardio- and cerebrovascular diseases [19]. 
The aim of our present study was to measure for the first time plasma levels of MASP-
1, MASP-2, MASP-3, and MAp44 in patients with T1DM and investigate possible 
associations with glycaemic control. 
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Materials and Methods 
Patients and control subjects 
We included 30 children and 45 adults with T1DM, and 17 children and 31 adults were 
included as non-diabetic, age and sex matched controls. All diabetes patients and 
control subjects were recruited at the University of Leeds. Control subjects were 
recruited through advertisement in the same hospital and unit where the patients were 
recruited. Other than background retinopathy, there were no significant microvascular 
complications in patients with T1DM and none were on any treatment other than 
insulin. We aimed to improve glycaemic control by adjusting insulin doses and regular 
patient contact, and collect repeat blood samples during the adult patients’ routine 
clinic follow- up, usually occuring in 3-4 months. Due to loss to follow-up or missed 
appointments, repeat blood samples were obtained from only 26 adult patients.  
Blood sampling was performed mid-morning after a light breakfast. Citrated plasma 
was separated within 2 hours of collection and stored frozen in aliquots until analysis. 
All participants, and in the case of underage individuals also their parents, gave written 
informed consent in accordance with the Declaration of Helsinki. The study was 
approved by the local ethics committee. 
 
Laboratory measurements 
We measured levels of MASP-1, MASP-2, and MASP-3 in citrated plasma samples 
which had been stored frozen in aliquots at -80°C until analysis. MASP-1 was 
determined with a competition ELISA using a MASP-1 specific antibody as described 
earlier [20]. Plasma levels of MASP-2 and MASP-3 were measured with commercial 
ELISA kits (Hycult Biotech, The Netherlands). MAp44 was determined with a time-
resolved immunofluorometric assay (TRIFMA) using a catching antibody and a A
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biotinylated detecting antibody in a sandwich-type assay as described previously [10]. 
Inter-assay coefficients of variance of all assays were below 15%. Routine parameters 
were determined in the routine diagnostic laboratories of the Leeds General Infirmary 
hospital. 
 
Statistical analysis 
Statistical analysis was performed with IBM SPSS Statistics, version 21. We used 
Kolmogorov-Smirnov and Shapiro-Wilk tests to check the data for normal distribution. 
Since most parameters did not follow the normal distribution in all groups, all data are 
displayed as median with interquartile range (25th percentile; 75th percentile). The 
appropriate parametric or non-parametric statistical tests were applied as indicated. 
Bivariate correlations of parameters were analysed using Pearson or Spearman 
correlation coefficients. Parameters were compared between two or multiple groups 
using the appropriate parametric (t-test or analysis of variance (ANOVA)) or non-
parametric (Mann-Whitney or Kruskal-Wallis test) methods. Differences between paired 
samples were tested by Wilcoxon or Friedman test. The Chi square test was used to 
compare categorical parameters between groups. A P-value of less than 0.05 was 
considered statistically significant.  
 
A
cc
ep
te
d 
A
rti
cl
e
7 
This article is protected by copyright. All rights reserved. 
 
Results 
Characterisation of diabetes patients and control subjects 
Our study population comprised the following groups: 1) children with T1DM and 
healthy control subjects matched for age and sex, and 2) adults with T1DM and healthy 
control subjects matched for age and sex. Demographic and clinical characteristics of 
these groups are shown in Tables 1 and 2. 
Plasma levels of MASPs and MAp44 in diabetes patients and controls 
MASP-1 and MASP-2 levels were significantly higher in children (Table 1) and adults 
(Table 2) with T1DM than in their respective control groups, whereas MASP-3 and 
MAp44 levels did not differ between patients and controls. When we compared MASP 
levels between all groups, MASP-1 levels were lowest in non-diabetic children and 
highest in adults with T1DM (Figure 1a). MASP-2 levels were lowest in non-diabetic 
children and young adults, and highest in adults with T1DM (Figure 1b). MASP-3 levels 
did not follow this trend and were lower in adults than in children irrespective of T1DM 
(Figure 1c). 
Effect of glycaemic control on levels of MASPs and MAp44 
There were significant correlations between MASP-1 levels and HbA1c in children with 
T1DM (Spearman correlation coefficient 0.456 (p=.011) and in adults with T1DM 
(0.482, p=<.001). In adults with T1DM, there was also a correlation between MASP-2 
levels and HbA1c (0.437, p=<.001), and both MASP-1 and MASP-2 levels correlated 
with the duration of T1DM (MASP-1 0.346, p=.004; MASP-2 0.359, p=.003). Neither 
MASP-3 nor MAp44 levels did correlate with HbA1c in any patient group.  A
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In a subgroup (n=26) of adult patients with T1DM, we measured levels of MASPs and 
MAp44 at baseline and 16±3 weeks after improving glycaemic control (shown in Table 
3). Overall, a moderate but statistically significant reduction in HbA1c was not 
associated with significant reductions in MASP levels. However, patients whose HbA1c 
improved by at least 10% of the baseline value did show significant intraindividual 
reductions in MASP-1 and MASP-3. There was also a trend towards a reduction in 
MASP-2 levels, but the large variation in MASP-2 levels may be the reason for a non-
significant result.  
Taken together, these results suggest that blood glucose levels  may represent a 
determinant of MASP levels, and in particular MASP-1 levels, in T1DM.  
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Discussion 
Although MBL is well known to be elevated in diabetes patients and thought to be 
involved in vascular complications of diabetes, plasma levels of the MBL-associated 
serine proteases, MASP-1, MASP-2, and MASP-3, and the regulator MAp44 have not 
yet been studied in patients with diabetes. Here we show for the first time that MASP-1 
and MASP-2 are elevated in patients with T1DM, that MASP-1 and MASP-2 levels 
correlate with HbA1c, and that glycaemic control may modulate MASP levels.  
Our results suggest that levels of MASPs, in particular MASP-1 and MASP-2,  may be 
linked to blood glucose levels. Recent data on MBL obtained in mouse models support 
this conclusion. MBL plasma levels were measured in mice before and seven weeks 
after inducing diabetes by streptozotocin. Diabetes induction led to an increase in MBL-
C that was associated with the increasing plasma glucose levels. This study suggested 
that MBL levels increase in mice as a consequence of diabetes [21]. Other studies 
have  shown that MBL knockout or insulin treatment protected hyperglycaemic mice 
from cardiac complications [22,23]. 
A possible link between hyperglycaemia and complement activation has been 
suggested by Fortpied et al [24]. They could show that MBL binds with high affinity to 
the glycation product fructoselysine and that this binding is associated with 
complement activation. Advanced glycation endproducts (AGEs) have been considered 
responsible for various adverse outcomes associated with insulin resistance and 
diabetes, such as inflammatory processes, endothelial damage, activation of blood 
coagulation, and vascular complications [25-27]. A
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Based on the results of our present study we conclude that diabetes features not only 
elevate plasma levels of MBL but also its associated serine proteases. The increase of 
MASPs in diabetes may be induced by the same underlying mechanisms that are 
responsible for the increase of MBL as a consequence of hyperglycaemia, or MASP 
levels increase secondary to the increase of MBL as their binding protein. The 
circulating complexes of MBL and MASPs bind to AGEs and this induces 
conformational changes leading to activation of MASP-1 and consequently MASP-2. 
We and others have shown that both MASP-1 and MASP-2 directly interact with blood 
coagulation factors prothrombin, fibrinogen, factor XIII, and thrombin-activatable 
fibrinolysis inhibitor, and hence can promote fibrin formation (as recently summarised 
by us [9]). This could eventually result in thrombotic complications. We therefore 
hypothesise that the axis “hyperglycaemia  elevated levels of MBL, MASP-1, MASP-
2  binding to AGEs  activation of MASP-1 and MASP-2  increased fibrin 
formation” may represent an important link between diabetes and its thrombotic 
vascular complications. 
Limitations of our study include the case-control design and the relatively small sample 
size. As there were no data in the literature on levels of MASPs and MAp44 in patients 
with diabetes, our intention was to perform this as a pilot study. The data presented in 
this work pave the way for future larger, prospective as well as mechanistic studies to 
determine the role of MASP levels and lectin pathway activation in the development of 
diabetes and its vascular complications, with the potential to discover new therapeutic 
targets. 
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Tables 
Table 1. Characteristics and plasma levels of MASPs in children with T1DM and 
matched controls. 
 T1DM children 
n=30 
Controls 
n=17 
P-value a) 
Age (years) 14.9   ( 12.7; 15.6) 14.4   ( 11.9; 15.4)  .319 
Weight (kg) 58.7   ( 52.4; 63.5) 50.8   ( 39.9; 60.2)  .068 
BMI (kg/m2) 21.9   ( 20.6; 22.9) n.d. - 
Total cholesterol 
(mmol/l) 
4.6   ( 4.0; 5.2) n.d. - 
Diabetes duration 
(months) 
73.1   ( 34.2; 104.2) n.a. - 
HbA1c (%) 9.3   ( 8.1; 10.1) n.d. - 
MASP-1 (µg/ml) 11.1   ( 9.3; 13.7) 7.9   ( 6.2; 11.5) .007  
MASP-2 (ng/ml) 420.9   ( 325.5; 509.8) 278.4   ( 201.3; 423.2) .008  
MASP-3 (µg/ml) 8.2   ( 7.0; 9.3) 7.6   ( 7.1; 9.2)  .364 
MAp44 (μg/ml) 1.9  (1.5; 2.1) 1.8  (1.4; 1.9) .298 
Continuous data are shown as median ( 25th percentile; 75th percentile). n = number; 
n.d. = not determined; n.a. = not applicable; a) Mann-Whitney test. 
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Table 2. Characteristics and plasma levels of MASPs in adults with T1DM and 
matched controls. 
 T1DM adults 
n=45 
Controls 
n=31 
P-value 
Age (years) 22.0   ( 19.0; 26.0) 23.0   ( 22.0; 26.0)  .390 a) 
Weight (kg) 71.9   ( 64.7; 78.8) 71.0   ( 63.0; 80.0)  .747 a) 
BMI (kg/m2) 23.2   ( 20.8; 25.7) 23.2   ( 21.7; 25.0)  .865 a) 
Smoking, yes:no (%) 8:36   (18:82) 1:30 (3:97)  .102 b) 
Microvascular com-
plications, yes:no (%) 
10:31   (24:76) 0:31   (0:100) .004 b) 
Creatinine (μmol/l) 89.5   ( 82.0; 100.0) 89.0   ( 79.0; 95.0)  .273 a) 
Total cholesterol 
(mmol/l) 
4.4   ( 3.9; 5.2) 4.1   ( 3.7; 5.0)  .142 a) 
Diabetes duration 
(months) 
108.0   ( 55.5; 162.0)) n.a. - 
HbA1c (%) 9.0   ( 8.0; 9.9) 5.4   ( 5.1; 5.5) <.001 a) 
MASP-1 (µg/ml) 12.5   ( 10.6; 15.5) 9.7   ( 8.3; 13.6) .003 a) 
MASP-2 (ng/ml) 
400.1   ( 330.7; 
580.8) 
290.4   ( 198.3; 
390.1) 
.001 a) 
MASP-3 (µg/ml) 4.8   ( 4.2; 5.6) 5.6   ( 4.4; 6.7)  .058 a) 
MAp44 (μg/ml) 1.7  (1.5; 1.9) 1.6  (1.5; 1.8) .725 a) 
Continuous data are shown as median ( 25th percentile; 75th percentile). n = number; 
n.d. = not determined; n.a. = not applicable; a) Mann-Whitney test; b) Chi square test. 
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Table 3. Effect of glycaemic control on plasma levels of MASPs in adults with T1DM. 
 
 Baseline 
 After 
improvement of 
glycaemic control 
P-value a) 
for intraindividual 
change  
All patients in this subgroup (n=26) 
HbA1c (%) 9.8   ( 9.2; 11.1) 9.0   ( 7.9; 10.5) .001  
MASP-1 (µg/ml) 16.5   ( 14.8; 20.2) 15.4   ( 13.4; 18.7)  .078 
MASP-2 (ng/ml) 452.9   ( 315.7; 
575.5) 
362.6   ( 237.3; 
537.0) 
 .170 
MASP-3 (µg/ml) 4.7   ( 4.1; 5.7) 4.6   ( 3.9; 5.5)  .069 
MAp44 (μg/ml) 2.0  (1.7; 2.2) 1.8  (1.6; 2.1) .054 
Patients whose glycaemic control improved most (HbA1c down by at least 10%) 
(n=12) 
HbA1c (%) 10.4   ( 9.3; 14.1) 8.2   ( 7.1; 9.7) .002  
MASP-1 (µg/ml) 16.9   ( 15.2; 21.5) 14.9   ( 12.8; 18.5) .012  
MASP-2 (ng/ml) 487.1   ( 350.0; 
649.7) 
441.5   ( 316.7; 
635.9) 
.136 
MASP-3 (µg/ml) 5.3   ( 4.1; 6.5) 4.8   ( 3.8; 5.4) .011  
MAp44 (μg/ml) 1.9  (1.7; 2.2) 1.8  (1.7; 2.3) .625 
Data are shown as median ( 25th percentile; 75th percentile). n = number; a) Wilcoxon 
signed-rank test. 
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Figure legends 
Fig. 1. Plasma levels of MASPs in patients with diabetes and control subjects showing 
(a) MASP-1, (b) MASP-2, and (c) MASP-3 levels. Boxes represent median, 25th and 
75th percentiles, whiskers show the 10th and 90th percentiles, and dots are values 
outside these percentiles. Groups were compared using the Mann-Whitney test and the 
p-value is indicated; ns is non significant. 
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